Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder (ADHD) who took once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention. This improvement was measured by average of Permanent Product Measure of Performance (PERMP) total scores of all six time points measured across the assessment day (two, four, eight, 10, 12 and 14 hours after administration) as well as at each time point measured. This is the first study published in a peer-reviewed journal to demonstrate efficacy data for adults at 14 hours postdose of an oral long-acting stimulant medication for ADHD approved by the U.S. Food and Drug Administration (FDA).
Vyvanse is a prescription medicine for the treatment of ADHD. Efficacy was based on two controlled trials in children aged six to 12 and two controlled trials in adults. Vyvanse should be used as part of a total treatment program that may include counseling or other therapies.
"Because ADHD symptoms may extend into the evening for many adults, the availability of treatments that provide symptom improvement throughout the day is important," said Matthew Brams, M.D., study author and Clinical Assistant Professor of Psychiatry at Baylor College of Medicine. "Physicians who want to help their adult patients manage their ADHD symptoms beyond the work day may want to consider Vyvanse, which has demonstrated significant efficacy throughout the day, even at 9 PM when taken at 7 AM."
Mapping human biology: Human Cell Atlas leads a new era in precision medicine